Navigation Links
ANA598 in Medical News

Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that it has initiated dosing ANA598 in patients chronically infected with hepatitis C virus (HCV) in a Phase Ib study. ANA598 is an investigational, oral, non-nucleoside polymerase inhibi...

Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering

...addition, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ana598 will not have unforeseen safety issues, will have favorable results in future clinical trials, will maintain fast track designation or will receive re...

Anadys Pharmaceuticals to Present at the Citi Biotech Day

... Officer of Anadys, will provide an overview of Anadys and an update on its ana598 clinical program in hepatitis C. The corporate presentation will be si...predictive of future results, and Anadys cannot provide any assurances that ana598 or ANA773 will not have unforeseen safety issues, will have favorable resul...

Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights

...ich we now have begun to see. We have established ana598 as a potent antiviral, demonstrating in three days... by significant increases in development costs for ana598 and ANA773. General and administrative expe...ially offset by increases in development costs for ana598 and ANA773. For the twelve months ended December ...

Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results

...ng statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ana598 and ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk fa...

Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference

...will provide an overview of Anadys and an update on its clinical programs: ana598 and ANA773 in hepatitis C and ANA773 in cancer. Additionally, Dr. Worl...predictive of future results, and Anadys cannot provide any assurances that ana598 or ANA773 will not have unforeseen safety issues, will have favorable resul...

Anadys Pharmaceuticals to Present at BIO InvestorForum 2007

...ef Executive Officer of Anadys Pharmaceuticals, Inc. will present an overview of Anadys and an update on its two development-stage product candidates, ana598 and ANA773. The presentation will be simultaneously webcast and can be accessed on the Company's website at http://www.anadyspharma.com . Listeners ...
ANA598 in Medical Technology

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today the results of a Phase I clinical trial of ANA598 in h...

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

Safety and Pharmacokinetic Results in Healthy Volunteers to be Presented at AASLD SAN DIEGO, Sept. 24 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today preliminary results of a Phase I clinical trial of ANA598 in healthy volun...

Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection

ANA598 demonstrates significant antiviral activity in vivo SAN DIEGO, Jan. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced preliminary data today from two studies of ANA598, a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, in...

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

Company Developing Non-Nucleoside Polymerase Inhibitor for Treatment of Hepatitis C SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today the initiation of dosing in a Phase I clinical trial of ANA598, an investig...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

... (EASL) in Copenhagen, Denmark. In the study, ana598 treatment resulted in rapid and sustained reductio...showed evidence of viral rebound while on ANA598. ana598 was well-tolerated in this short term study and th...his study is very encouraging for the prospects of ana598 when used in combination with other HCV agents. W...

ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients

...estigational non-nucleoside polymerase inhibitor. ana598 was very well-tolerated and demonstrated potent an... Patients in the first cohort received 200 mg ana598 (n=8) or placebo (n=2), twice-daily (bid) for thre...s who received ANA598. Three patients who received ana598 were genotype 1a and demonstrated a median viral l...

Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference

...ing statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ana598 and ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk fac...

Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV

... Expanded HCV Development Presence Includes ana598 and ANA773 Acting via Independent but Potentially Complementary Mechanisms Conference Call Today at 2:00 PM PDT SAN DIEGO,...

Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research

...ntation reported several preclinical attributes of ana598 that support the potential for beneficial combinat... with several other anti-HCV agents. Specifically, ana598 was reported to be highly synergistic with interfe... with ribavirin in cell-based assays. Furthermore, ana598 retained full activity against a number of replico...

Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses

... ana598 demonstrates favorable preclinical antiviral, meta...pported the decision announced in June to progress ana598 to IND enabling studies and subsequent clinical ev...on expected to commence in the first half of 2008. ana598 is a potent, low-nanomolar inhibitor of HCV genoty...
ANA598 in Biological News

Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference

...er of Anadys, will provide an overview of Anadys and its clinical programs: ana598 and ANA773 in hepatitis C and ANA773 in cancer. The presentation will ...predictive of future results, and Anadys cannot provide any assurances that ana598 or ANA773 will not have unforeseen safety issues, will have favorable resul...
ANA598 in Biological Technology

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced finalization of the protocol for the Company's Phase II trial of ANA598 in combination with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance o...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced a strategic restructuring to focus its operations on the development of ANA598, in particular a proposed Phase II study in hepatitis C patients of ANA598 in combination with pegylated int...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...ositioned to continue advancing the development of ana598 as a treatment for chronic hepatitis C," said Stev...eral important elements, including twelve weeks of ana598 combination treatment and a randomized exploration...verall duration of HCV therapy in conjunction with ana598 treatment. We look forward to receiving the first...

Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results

... example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ana598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... ready in mid-2009 for the first Phase II study of ana598 in combination with pegylated interferon and ribav...dy with the potential to demonstrate the impact of ana598 on durable clinical benefit, known as SVR, in HCV ...m a $1.7 million increase in development costs for ana598 in the first quarter of 2009 compared to the first...

Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results

...to provide an update on its development programs, including a review of the ana598 antiviral data that will be presented that day at the 44th Annual Meeting o...predictive of future results, and Anadys cannot provide any assurances that ana598 or ANA773 will not have unforeseen safety issues, will have favorable resul...

Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry

...er of Anadys, will provide an overview of Anadys and its clinical programs: ana598 and ANA773 in hepatitis C and ANA773 in cancer. The corporate presenta...predictive of future results, and Anadys cannot provide any assurances that ana598 or ANA773 will not have unforeseen safety issues, will have favorable resul...

ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection

...ration (FDA) has granted fast track designation to ana598 for the treatment of chronic hepatitis C virus (HCV) infection. ana598 is Anadys' investigational hepatitis C non-nucleos... enrolling patients in a Phase Ib study evaluating ana598 for the treatment of patients chronically infected...

Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

...nadys, will provide an overview of Anadys and its three clinical programs: ana598 and ANA773 in hepatitis C and ANA773 in cancer. The presentation w...predictive of future results, and Anadys cannot provide any assurances that ana598 or ANA773 will not have unforeseen safety issues, will have favorable resul...

Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights

... Anadys. "We completed our first clinical study of ana598 in healthy volunteers and have now completed the h... programs were offset by a significant increase in ana598 development costs. General and administrative ex...n, and expects to initiate patient dosing shortly. ana598 will be administered to naive genotype 1a and 1b p...
Other Tags
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
(Date:4/17/2014)... have hit on a novel method to help ... and most effective treatment possible., Kidney stones represent ... developing world. If left untreated, apart from being ... and other complications. In many patients treated successfully, ... more effective pathological approach to diagnosis and treatment ...
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
(Date:4/17/2014)... Indiana University researchers have detected new early-warning signs of ... discovery could have far-reaching implications for the diagnosis and ... over 25 million Americans. , "We had not expected ... such early stages," said Ann Elsner, professor and associate ... author of the study. "We set out to study ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
Other Contents